Cefixime
 | |
|---|---|
| Systematic (IUPAC) name | |
| (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
| Identifiers | |
| CAS number | 79350-37-1 |
| ATC code | J01DD08 |
| PubChem | CID 5362065 |
| DrugBank | APRD00583 |
| ChemSpider | 4514923 |
| UNII | 97I1C92E55 |
| KEGG | D00258 |
| ChEMBL | CHEMBL1541 |
| Chemical data | |
| Formula | C16H15N5O7S2 |
| Mol. mass | 453.452 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | 40% to 50% |
| Protein binding | Approximately 60% |
| Half-life | Variable Average 3 to 4 hours |
| Excretion | Renal and biliary |
| Therapeutic considerations | |
| Pregnancy cat. | B |
| Legal status | ? |
| Routes | Oral |
 (what is this?) (verify) | |
Cefixime is an oral third generation cephalosporin antibiotic. It is used to treat gonorrhea, tonsilitis, and pharyngitis.
The usual dose is 400 mg in two divided doses for up to 5-7 days.
It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA.
References
- McMillan A, Young H. (2007). "The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime". Int J STD AIDS 18 (4): 253–4. doi:10.1258/095646207780658971. PMID 17509176.
- ^ Adam D, Hostalek U, Tröster K. (1995). "5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy". Infection 23 (Suppl 2): S83–6. doi:10.1007/BF01742990. PMID 8537138.
Retrieved from : http://en.wikipedia.org/wiki/Cefixime
